Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
03 sept. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)
03 sept. 2024 08h30 HE
|
Imugene Limited
Three complete responses in azer-cel allogeneic CD19 CAR T Phase 1b trial in blood cancer (Diffuse Large B-Cell Lymphoma)
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
26 août 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
12 août 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
08 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
07 août 2024 02h00 HE
|
Cellectis Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Provides Financial Results for the Second Quarter 2024
06 août 2024 16h30 HE
|
Cellectis Inc.
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273...
Monthly information on share capital and company voting rights
05 août 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
26 juil. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
25 juil. 2024 16h30 HE
|
Cellectis Inc.
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies for...